BLACK WOMEN ARE BECOMING HIV infected at rates 3 to 4 times higher than other women in the United States.1,2 Heterosexual acquisition has been the primary cause of infection for black women for well over a decade.3 In addition, black women have the highest rates for the majority of bacterial sexually transmitted infections (STIs) among women and for the viral STI herpes simplex virus-2 (HSV-2).4–7 Increasingly, data suggest that black women bear the burden of trichomoniasis,8 and that this STI is significantly more prevalent than that of gonorrhea and chlamydia combined.9,10 Moreover, all of these STIs have been individually associated with an increased risk of HIV acquisition and, potentially, with an increased risk of HIV transmission.11–14 Therefore, the high prevalence and incidence of the major STIs in black communities has the potential to make HIV another endemic STI, unless interventions are developed that explicitly identify and treat infected individuals.
To date, research has focused on coinfections between HIV and only one other STI in primarily high-risk populations (e.g., STI clinic patients). However, it is possible that individuals who are coinfected with HIV and another STI may have additional STIs, which may further alter STI natural history and enhance transmission synergy.14 Moreover, sex mixing patterns in black communities suggest that high-risk individuals (e.g., those more likely to have STIs) are just as likely to have sex with low, medium, or other high-risk individuals.6 A dynamic of multiply infected individuals interacting with both lower- and higher-risk sex partners could contribute to the high STI incidence consistently observed in black communities.
A possible caveat to this scenario is that HIV-infected individuals with multiple STIs may suffer increased morbidity and, therefore, be less sexually active than others. However, given the high prevalence of asymptomatic infection, particularly for women (40% asymptomatic with gonorrhea,15 75% with chlamydia,16 50% with Trichomonas vaginalis,17 and 85% with HSV-218) and a subsequent lack of infection status knowledge, morbidity may not be a potent barrier to sexual activity. Furthermore, the association among HIV, substance use, and sex risk,19,20 combined with the high cost of drug use could compel some HIV-infected individuals to be more sexually active than others. This may be particularly true for low income HIV-infected women, since they often rely on sex as a primary means to support their drug use.21
The current study examines the prevalence of multiple STIs among urban black women who use drugs, whether HIV-infected women are more likely than uninfected women to have multiple STIs and any differences in sex risk practices and partnerships between HIV-infected and uninfected women in a high-HIV prevalence community in New York City. In addition, since STI testing and treatment require access to medical care, women's current utilization of the health care system is also assessed.
Materials and Methods
Participants were black women recruited in central Brooklyn, NY, where active drug markets have been established for many years. Detailed recruitment methods have been reported elsewhere.22 In brief, eligible women self-identified as black, were aged 18 (or aged 16 and 17 and living as emancipated minors), used heroin, crack, or noncrack cocaine in the past 30 days or used marijuana daily, and had no plans to change residence. Eligibility was determined through screening interviews and urine toxicologies that screened for cocaine, opiate, and tetrahydrocannabinol metabolites. A broad drug use eligibility criterion was instituted to capture a range of women, as well as to limit incentives to lie about drug use.
Data were collected as part of a social network cohort study initiated in 2002. Additional funds were secured to screen for treatable STIs (i.e., gonorrhea, chlamydia, and trichomoniasis) and for HSV-2. Data collection for this component of the study began in March 2003 and continued through August 2005; 232 eligible black women were interviewed. Of these, 228 (98%) were screened for the full panel of STIs. This analysis is a cross-section of women at the time of their first full STI screening panel. Data were drawn from 147 baseline interviews and 81 follow-up interviews.
Women were administered a standardized questionnaire at a community based research site. Sociodemographics, health status, including self-reported HIV, STI and STI symptom status, and recent health care access were assessed. Questions assessing 30-day sex risk practices included the number of sex partners, condom use (i.e., consistent vs. inconsistent) and sex partner aggregate characteristics (e.g., 3 male partners and 1 female partner). Women's 30-day drug use practices included type of drug used (e.g., heroin, crack, or cocaine), frequency of use (i.e., daily or less than daily), mode of administration (e.g., injected or smoked) and drug treatment history. With few exceptions, (e.g., number of sex partners, which was examined as both a dichotomous and a continuous variable), variables were dichotomized to facilitate comparisons of the presence or absence of a risk factor with STI status.
Postinterview, women received pretest counseling and screening for a panel of STIs, including HIV, HSV-2, primary or secondary (1°/2°) syphilis, gonorrhea, chlamydia, and trichomoniasis. Blood specimens for HIV, HSV-2, and 1°/2° syphilis serotesting were collected using venipuncture. Women self-administered vaginal swabs to collect specimens for gonorrhea, chlamydia, and trichomoniasis.23 Women who were menstruating agreed to either provide a urine sample for STI testing or to return when they were no longer menstruating; all but 4 respondents complied; less than 5% of samples were urine. At the completion of screening, women were scheduled to return for their results. Respondents who screened positive were referred to local health care providers. Women were compensated for study participation. All respondents provided informed consent and the study protocol was approved by the Columbia University Institutional Review Board.
A repeated enzyme immunoassay (Vironostika; Durham, NC) with Western blot confirmation (Bio-Rad; Redmond, WA) was administered to detect HIV antibodies. The HSV-2 type-specific IgG antibody test (HerpeSelect HSV-2 ELISA, Focus Technologies, Cypress, CA) was used for HSV-2 screening; specimens with an index ratio ≥1.1 were designated HSV-2 seropositive. The IMPACT rapid plasma reagin card test and confirmatory fluorescent treponemal antibody absorption assay were used to detect antibodies to Treponema pallidum (i.e., syphilis). Among participants with a reactive fluorescent treponemal antibody absorption assay, an rapid plasma reagin titer ≥1:8 was classified as 1°/2° syphilis, and a titer <1:8 indicated tertiary, latent, or resolved syphilis. Specimens for gonorrhea and chlamydia were detected using real-time polymerase chain reaction (BDProbeTec ET CT/NG amplified DNA assays, BD, Franklin Lakes, NJ). Trichomoniasis specimens were resuspended in 200 μL of Tris-EDTA buffer and extracted via the Roche Magna Pure LC Robot with a positive processing control and a negative processing control. Extracted specimens and controls were subsequently analyzed on the Roche Lightcycler for detection of trichomoniasis by FRET-based real-time polymerase chain reaction assay.24,25
The primary goals of this study were to (a) describe the extent of STI coinfection and risk practices among urban black women who use drugs and (b) test the hypothesis that HIV-infected women are more likely to have multiple STIs than HIV-uninfected women. An “Index of Infection” was created to describe the extent of coinfection by summing the number of positive STI screens, (excluding HIV), for a possible score range of 0 to 5 (i.e., HSV-2, 1°/2° syphilis, gonorrhea, chlamydia, and trichomoniasis). This synthetic methodology has previously been used to describe the extent of antibiotic resistance of Staphylococcus aureus in a drug using population, as well as to compare the extent of S. aureus antibiotic resistance by HIV serostatus.26 Chi-square tests were used to examine differences between categorical variables in univariate analyses and the Student t test was used to examine differences between means of continuous dependent variables (e.g., the Index of Infection). The Wilcoxon 2-sample test was used to compare the medians of nonnormally distributed variables (e.g., number of sex partners) and Spearman's correlation was used to compare relationships between the Index of Infection and continuous variables. Linear regression models were developed to identify correlates of the Index of Infection in addition to HIV status. All sociodemographic, health status, sex risk, and drug use practices that were statistically significant at P <0.20 in univariate analyses were entered into a multivariate linear regression model, which used stepwise backward elimination to arrive at a final model. Factors believed to be associated with multiple STIs and HIV status a priori (i.e., age, STI symptoms, and income) were also forced into the model. Two-tailed P values are significant at P <0.05; Fisher exact test P values are reported when cells have expected counts of less than five. SAS version 9.1.3 was used for all statistical analysis (SAS Institute; Cary, NC).
Table 1 compares the sociodemographic characteristics of the 228 eligible black women by HIV status. The women had a mean age of 34 (SD 10; range 17–57). The mean income from legal or informal employment and public benefits in the past 30 days was $468 (SD $668; range $0–$4183).
Most (n = 202, 89%) women reported having ever been tested for HIV infection; 138 (61%) had been tested in the year before interview. Thirty-eight (17%) women tested HIV seropositive; 29 (13%) women knew themselves to be HIV infected. Among the 29 women who knew themselves to be HIV infected, 12 (41%) reported receiving antiretroviral therapy.
Sexually Transmitted Infections
The prevalence of the 5 other STIs is as follows: HSV-2 (n = 180, 79%), 1°/2° syphilis (n = 2, <1%), trichomoniasis (n = 84, 37%), chlamydia (n = 25, 11%), and gonorrhea (n = 5, 2%). Excluding HIV, the mean number of STIs was 1.3 (SD 0.7; range 0–3). Few women knew they were currently infected: HSV-2 (n = 16, 7%), 1°/2° syphilis (n = 1, <1%), trichomoniasis (n = 6, 3%), chlamydia (n = 8, 4%), and gonorrhea (n = 4, 2%), despite the fact that 76 (33%) women reported receiving medical care in last 30 days and two-thirds (64%) had received care in the past 3 months.
HIV-infected women were significantly more likely to have multiple positive test results than uninfected women (Table 2). However, HIV-infected women were no more likely than uninfected women to report STI symptoms (21% vs. 26%, P = 0.50). Excluding HIV therapy, none of the HIV-infected women and only 1 uninfected woman reported having been treated for STIs in the 6 months before interview.
Sex Practices and Partnerships
The majority (190% or 83%) of women were sexually active in the last 30 days: 163 (71%) women reported sex exclusively with men, 15 (7%) reported sex exclusively with women and 12 (5%) reported sex with both men and women. Almost three-quarters (n = 129, 74%) of 175 women who were sexually active with men reported inconsistent condom use. There were no significant differences in sexual activity or condom use between HIV infected and uninfected women (Table 3).
In the past 30 days, women reported 2.6 male sex partners on average (SD 8, median 1.0; range 0–100); no differences in the mean (or median) number of male sex partners between HIV infected and uninfected women were observed (mean 2.5 vs. 2.7, P = 0.89; median 1 vs. 1, P = 0.89). Moreover, there were no differences in the mean (or median) number of male sex partners not known to be HIV infected between HIV-infected and uninfected women (mean 2.0 vs. 2.6, P = 0.46; median 1 vs. 1, P = 0.50), although HIV-infected women were more likely to report sex with male partners known to be HIV infected. The only other significant in sex practices observed was current participation in sex work: HIV-infected women were more likely to report current sex exchanges than uninfected women (P = 0.05). This remained true for women who knew themselves to be HIV infected (38% vs. 20%, P = 0.03).
Thirty-Day Drug Use Practices
Recent drug use practices by HIV status are described in Table 4. Almost one-third of women (73 or 32%) reported daily hard drug use (i.e., crack, heroin or cocaine) in the past 30 days, and 61 (27%) used crack daily. Few (9%) women currently injected drugs, though 43 (19%) indicated a lifetime history of intravenous drug use; 12 (32%) HIV-infected women reported a history of intravenous drug use. Alcohol and marijuana use were ubiquitous in this population: 164 (72%) women drank alcohol and 186 (82%) smoked marijuana in the 30 days before interview. Just over half (n = 124, 54%) of the women had a history of attending drug treatment programs.
Correlates of the Index of Infection
A linear regression model was developed to examine the correlates of the Index of Infection in addition to HIV status. Variables considered in model development were sociodemographic measures, sex practices, STI symptoms, and drug use practices. In univariate analyses, only age and crack use were associated with the Index of Infection, though 3 additional variables satisfied model development criteria (P <0.20) and were included in preliminary modeling (i.e., number of male sex partners, age as a continuous variable and sex work; daily hard drug use was not included because of a high correlation with crack use). Univariate relationships between the potential risk factors examined and the Index of Infection, as well as the final statistical model are presented in Table 5. Crack use, but not HIV status, was significantly associated with the Index of Infection.
Almost one-fifth (17%) of the women in this study who are vulnerable to both acquiring and transmitting STIs were HIV infected. HIV-infected women were significantly more likely than uninfected women to screen positive for multiple STIs (other than HIV). The overwhelming majority of women were currently sexually active; almost all women sexually active with men had partners not known to be HIV infected and consistent condom use was rare. HIV-infected women were similar to uninfected women in sex practices and partnerships, with the notable exception of sex work in which almost twice as many HIV-infected women reported participation. Current crack use was the only significant correlate of screening positive for multiple STIs after controlling for other risk factors thought to contribute to STI positive status, including HIV seropositive status.
A range of STIs seem to be endemic in this population: 4 in 5 women screened positive for HSV-2, 2 in 5 for trichomoniasis and nearly 1 in 5 for HIV. Although HIV-infected women were significantly more likely than uninfected women to screen positive for multiple STIs, only 17% of HIV-seronegative women screened negative for all STIs examined in this study. In fact, 3 quarters of HIV-seronegative women were seropositive for HSV-2. HSV-2 has been strongly implicated in the acquisition of HIV and research suggests it may facilitate HIV transmission as well.13,27 Effective, relatively low-cost HSV-2 suppressive therapy is currently available; however, most women were unaware of their HSV-2 seropositive status, although many reported symptoms. This was also true of trichomoniasis, for which treatment is inexpensive, of short duration, and curative.28 A high prevalence of STIs has also been documented in other research conducted among subgroups of the population who use drugs.8,29–31 Even more troubling is the fact that two-thirds of women reported receiving medical care in the past 3 months. Although women reported accessing health care, there seems to be no concerted effort by practitioners to address sexual health, a particularly shocking fact in light of surveillance statistics that document a high prevalence of HIV and all other reportable STIs in this community2 (J. Schillinger, MD, NYC DOHMH, October 11, 2007, personal communication).
The majority of women in this study were sexually active and at levels higher than other comparable cohorts of black women who use crack cocaine.20 Moreover, there were few differences in sex risk between HIV-infected and uninfected women, with the exception of greater sex work participation by HIV-infected women. Although there is clearly a need for intervention, the outcomes of sex risk reduction interventions for HIV-seropositive women have been mixed, documenting both increased32–34 and decreased sex risk.35 Crack use has been implicated in sex risk in this research; over half of the women in this study reported current crack use. Although some research suggests that crack is no longer the public health issue that it once was,36 it was found to be uniquely and strongly associated with screening positive for multiple STIs in this study. This suggests that crack use remains a localized but intransigent public health problem that may contribute to sustaining STI epidemics. Moreover, crack use deserves special attention because over the past 2 decades it has devastated the primarily black, low-income communities where its use is most prevalent and likely accounts at least in part for the disparities seen not only in health, but also in the crime, violence, and poverty that fuels both drug use and the sex trade.37
The spatial clustering of STIs in well-defined geographical locations has increasingly become a focus in prevention planning.38,39 This study sought to determine if STIs clustered at the individual level in a geographically well defined community of high HIV and STI prevalence. As hypothesized, HIV-infected women were significantly more likely than uninfected women to test positive for multiple STIs. This finding suggests that both the source and the means of epidemic potential and maintenance may be quite concentrated. Multiply infected individuals may represent members of core groups that constitute reservoirs of infection within geographical locations of STI clustering.40,41
Core group members with multiple STIs may be identified through increased STI testing. In addition to improved STI screening procedures at medical settings in high prevalence communities, prevention strategies that include screening at nonclinical settings could contribute significantly to the disruption of STI and HIV transmission. In fact, women in this study who returned for their test results reported a 6-fold increase in STI treatment over time, even in the absence of on-site treatment.42 Rapid point of care tests and treatment implemented in novel settings, including those where street based sex workers and their clients may be found, could disrupt STI transmission.43,44 Moreover, this approach is consistent with national recommendations for HIV-infected individuals.45 However, and in addition, it will be necessary to address the extensive substance use problems that often occur in tandem with STI epidemics, in order to effectively disrupt disease transmission.46
Much of the data used in this cross-sectional study are based on self-report and, therefore, should be interpreted with caution. Although these data do not directly address the increase in biologic synergism that may occur with multiple STIs, multiply STI-infected individuals are expected to experience at least the transmission potential established for those who are coinfected with HIV and one other STI. The Index of Infection developed for this analysis is a simple risk indicator and does not differentiate among viral, bacterial or parasitical STIs, which each have different capabilities for increasing HIV transmission potential. Therefore, it is difficult to determine if transmission is mediated by biologic factors, increased exposure to infection through sex work, or simply through the high background STI prevalence, (of predominantly asymptomatic individuals), that increases all individual's risk of acquiring (or transmitting) STIs. The 30-day risk assessment period provides a snapshot of risk and may be a conservative estimate of sex mixing patterns. Although a variety of strategies were used to access women in this hidden community, future research efforts should consider other recruitment methodologies,47,48 as well as conducting multisite studies to increase sample size and diversity.
Several STIs, including HIV, seem to be endemic among black women who use drugs in this community. Many women were coinfected with multiple STIs, particularly those who were HIV seropositive. Therefore, in addition to the known geographical clustering of HIV and STIs, STIs were also found to cluster at the individual level. Although participation in high-risk sex practices with both higher- and lower-risk sex partners was common, few women knew themselves to be infected with STIs other than HIV. Core groups of multiply STI infected individuals may unknowingly but efficiently contribute to high STI incidence rates. Innovative methods to rapidly screen and treat STI-infected individuals may prove to be a cost-effective use of HIV prevention resources. In addition, the simultaneous provision of treatment for crack cocaine use is advisable, since crack use seems to exacerbate STI transmission potential.
3. Centers for Disease Control and Prevention. Update: Trends in AIDS incidence—United States. MMWR Morb Mortal Wkly Rep 1997; 46:861–867.
4. Aral SO, Hughes JP, Whitttington W, et al. Sexual mixing patterns in the spread of gonococcal and chlamydial infections. Am J Public Health 1999; 89:825–833.
5. Eng TR, Butler WT. The Hidden Epidemic Confronting Sexually Transmitted Diseases. Washington, DC: National Academy Press, 1997.
6. Laumann EO, Youm Y. Racial/ethnic group differences in the prevalence of sexually transmitted diseases in the United States: A network explanation. Sex Transm Dis 1999; 26:250–261.
7. Smith DK, Gwinn M, Selik RM, et al. HIV/AIDS among African Americans: Progress or progression? AIDS 2000; 14:1237–1248.
8. Sorvillo F, Smith L, Kerndt P, et al. Trichomonas vaginalis
, HIV and African-Americans. Emerg Infect Dis 2001; 7:927–932.
9. Cates W Jr., American Social Health Association Panel. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. Sex Transm Dis 1999; 26:S2–S7.
10. Schwebke JR, Burgess D. Trichomoniasis. Clin Microbiol Rev 2004; 17:794–803.
11. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: The contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999; 75:3–17.
12. Laga M, Manoka A, Kivuvu M. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: Results from a cohort study. AIDS 1993; 7:95–102.
13. Reynolds SJ, Quinn TC. Developments in STD/HIV interations: The intertwining epidemics of HIV and HSV-2. Infect Dis Clin North Am 2005; 19:415–425.
14. Wasserheit JN. Interrelationships between human immunodeficiency viurs infection and other sexually transmitted diseases. Sex Transm Dis 1992; 19:61–77.
15. Bozicevic I, Fenton K, Martin IMC, et al. Epidemiological correlates of asymptomatic gonorrhea. Sex Transm Dis 2006; 33:289–295.
16. Meyers DS, Halvorson H, Luckhaupt S. Screening for chlamydial infection: An evidence update for the U.S. preventive services task force. Ann Intern Med 2007; 147:135–142.
17. Fouts AC, Kraus SJ. Trichomonas vaginalis
: Reevaluation of its clinical presentation and laboratory diagnosis. J Infect Dis 1980; 141:137–143.
18. Leone P. Reducing the risk of transmitting genital herpes: Advances in understanding and therapy. Curr Med Res Opin 2005; 21:1577–1582.
19. Hader SL, Smith DK, Moore JS, et al. HIV infection in women in the United States. JAMA 2001; 286:1186–1192.
20. Wechsberg WM, Lam WKK, Zule WA, et al. Efficacy of a woman-focused intervention to reduce HIV risk and increase self-sufficiency among African American crack abusers. Am J Public Health 2004; 94:1165–1173.
21. Miller M, Neaigus A. An economy of risk: Resource acquisition strategies of inner city women who use drugs. Int J Drug Policy 2002; 13:399–408.
22. Miller M, Korves CT, Fernandez T. The social epidemiology of HIV transmission among African American women who use drugs and their social network members. AIDS Care 2007; 19:858–865.
23. Wendel KA, Erbelding EJ, Gaydos CA, et al. Trichomonas vaginalis
polymerase chain reaction compared with standard diagnostic and therapeutic protocols for detection and treatment of vaginal trichomoniasis. Clin Infect Dis 2002; 35:576–580.
24. Hardick J, Yang S, Lin S, et al. Use of the Roche LightCycler instrument in a real-time PCR for Trichomonas vaginalis
in urine samples from females and males. J Infect Dis 2003; 41:5619–5622.
25. Madico G, Quinn TC, Rompalo A, et al. Diagnosis of Trichomonas vaginalis
infection by PCR using vaginal swab samples. J Clin Microbiol 1998; 36:3205–3210.
26. Miller M, Cespedes C, Vavagiakis P, et al. Staphylococcus aureus
colonization in a community sample of HIV infected and uninfected drug users. Eur J Clin Microbiol Infect Dis 2003; 22:465–469.
27. Serwada D, Gray RH, Sewankambo NK. Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: A nested case-control study in Rakai, Uganda. J Infect Dis 2003; 188:1492–1497.
28. Van der Pol B. Trichomonas vaginalis
infection: The most prevalent nonviral sexually transmitted infection receives the least public health attention. Clin Infect Dis 2007; 44:23–25.
29. Plitt SS, Garfein RS, Gaydos CA, et al. Prevalence and correlates of Chlamydia trachomatis
, Neisseria gonorrhoeae
, Trichomonas vaginalis
infections, and bacterial vaginosis among a cohort of young injection drug users in Baltimore, Maryland. Sex Transm Dis 2005; 32:446–453.
30. Latka M, Ahern J, Garfein RS, et al; Collaborative Injection Drug User Study Group. Prevalence, incidence, and correlates of chlamydia and gonorrhea among young adult injection drug users. J Subst Abuse 2001; 13:73–88.
31. Hwang LY, Ross MW, Zack C, et al. Prevalence of sexually transmitted infections and associated risk factors among populations of drug abusers. Clin Infect Dis 2000; 31:920–926.
32 Brewer TH, Zhao W, Metsch LR, et al. High-risk behaviors in women who use crack: Knowledge of HIV serostatus and risk behavior. Ann Epidemiol 2007; 17:533–539.
33. Timpson SC, Williams ML, Bowen AM, et al. Condom use behaviors in HIV-infected African American crack cocaine users. Subst Abus 2003; 24:211–220.
34. Wilson TE, Gore ME, Greenblatt R, et al. Changes in sexual behavior among HIV-infected women after initiation of HAART. Am J Public Health 2004; 94:1141–1146.
35. Inciardi JA, Surratt HL, Kurtz SP, et al. The effect of serostatus on HIV risk behaviour change among women sex workers in Miami, Florida. AIDS Care 2005; 17:S88–S101.
36. Golub AL, Johnson BD. Crack's Decline: Some Surprises Across U.S. Cities. Research in Brief. Washington, DC: National Institute of Justice, 1997.
37. Ratner MS, ed. Crack Pipe as Pimp: An Ethnographic Investigation of Sex-for-Crack Exchanges. New York: Lexington Books, 1993.
38. Aral SO, Lipshutz J, Blanchard J. Drivers of STD/HIV epidemiology and the timing and targets of STD/HIV prevention. Sex Transm Dis 2007; 83:i1–i4.
39. Marmot M. The Status Syndrome: How Social Standing Affects Our Health and Longevity. New York: Henry Holth and Company, 2004.
40. Wasserheit JN, Aral SO. The dynamic topology of sexually transmitted disease epidemics: Implications for prevention strategies. J Infect Dis 1996; 174:S201–S213.
41. Zenilman JM, Ellish N, Fresia A, et al. The geography of sexual partnerships in Baltimore: Applications of core theory dynamics using a geographic information system. Sex Transm Dis 1999; 26:75–81.
42. Miller M, Liao Y, Manchikanti-Gomez A, et al. Prevalence and incidence rates of Trichomonas vaginalis
among African American women in New York City who use drugs. J Infect Dis. 2008; 197(4): 503–509.
43. Huppert JS, Mortensen JE, Reed JL, et al. Rapid antigen testing compares favorably with transcription-mediated amplification assay for the detection of Trichomonas vaginalis
in young women. Clin Infect Dis 2007; 45:194–198.
44. Gaydos CA. Rapid tests for sexually transmitted diseases. Curr Infect Dis Rep 2006; 8:115–124.
45. Recommendations of CDC, the Health Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Incorporating HIV prevention into the medical care of persons living with HIV. MMWR Recomm Rep 2003; 52(RR-12):1–24.
46. Miller M. The dynamics of substance use and sex networks in HIV transmission. J Urban Health 2003; 80:iii88–iii96.
47. Heckathorn D. Respondent driven sampling: A new approach to the study of hidden populations. Soc Probl 1997; 44:174–199.
48. Thompson SK, Seber GAF. Adaptive Sampling. New York, NY: John Wiley and Sons, 1996.